#USA #New York #Gross Law Firm #Actinium Pharmaceuticals #ATNM

Important Notice for Actinium Pharmaceuticals Investors

The Gross Law Firm has released a significant notice intended for shareholders of Actinium Pharmaceuticals, Inc. (NYSE: ATNM). This advisory pertains to a class action lawsuit that could affect many investors who acquired stock during a specific timeframe.

Class Action Overview

The class action covers shareholders who purchased shares of Actinium Pharmaceuticals from October 31, 2022, to August 2, 2024. It’s vital for these individuals to understand their rights and the implications of this lawsuit. Currently, shareholders are encouraged to reach out to the law firm to discuss opportunities for potential lead plaintiff appointments. However, becoming a lead plaintiff is not a requirement for participation in any potential settlements or recoveries.

Allegations Presented

The core of the lawsuit is grounded in allegations that the company's statements regarding its Phase 3 Sierra trial were misleading or false. Here are the main allegations:
1. Misrepresentation of Trial Data: The complaint suggests that the data presented regarding the Sierra trial is unlikely to meet the FDA's standards necessary for the approval of the drug Iomab-B.
2. Inadequate Disclosure: It is claimed that the additional analyses provided to the FDA, which were meant to show improved overall survival rates, are also unlikely to suffice under the FDA's guidelines.
3. Expected FDA Response: Due to the aforementioned factors, there is a strong likelihood that the FDA will not review the Iomab-B application, or if they do, it may be rejected in its current form.
4. Misleading Statements: This culminates in the assertion that the defendants made materially misleading statements about the company's operations and prospects, which could mislead shareholders.

Critical Dates

Shareholders are urged to register for this class action as soon as possible. The deadline to file a lead plaintiff application is May 27, 2025. This date is essential for those wishing to actively participate in the case. Interested investors can complete their registration through the following link: Register Here.

Communication for Shareholders

Upon registering as a shareholder affected by this lawsuit, individuals will be enrolled in a portfolio monitoring software that provides status updates throughout the case's progression. This feature allows investors to stay informed about any developments in the case, ensuring that they are not left in the dark.

Why Choose Gross Law Firm?

The Gross Law Firm has established a reputation as a nationally recognized class action litigation firm. Their mission revolves around protecting the rights of investors who have fallen victim to misleading business practices and fraudulent activities. They actively work towards ensuring that companies adhere to ethical business standards and good corporate citizenship, making a sizeable impact in securing justice and restitution for aggrieved investors. Attorney advertising is noteworthy, as previous success does not guarantee similar outcomes for current and future cases.

Contact Information

For those with questions or needing assistance, the Gross Law Firm is readily available:

• - Address: The Gross Law Firm, 15 West 38th Street, 12th floor, New York, NY, 10018
• - Email: info@grosslawfirm.com
• - Phone: (646) 453-8903

Conclusion

Investors in Actinium Pharmaceuticals are encouraged to take prompt action regarding their involvement in this class action lawsuit. The potential implications of misleading statements on stock value can significantly affect their investments, and the time-sensitive nature of this class action necessitates immediate attention. By proactively registering for the class action, investors can safeguard their rights and position themselves for any potential recovery that arises from the lawsuit.